{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:34:28Z","timestamp":1792668868042,"version":"4.5.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T00:00:00Z","timestamp":1703376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.blre.2023.101164","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T11:33:20Z","timestamp":1703331200000},"page":"101164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A"],"prefix":"10.1016","volume":"64","author":[{"given":"Hussien Ahmed H.","family":"Abdelgawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2023.101164_bb0005","series-title":"WFH guidelines for the Management of Hemophilia","first-page":"1","volume":"26(S6)","author":"Srivastava","year":"2020"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2023.101164_bb0015","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0020","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0030","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/bloodadvances.2021006119","article-title":"Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study","volume":"6","author":"Lissitchkov","year":"2022","journal-title":"Blood Adv"},{"issue":"10274","key":"10.1016\/j.blre.2023.101164_bb0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.blre.2023.101164_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101164_bb0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2021-150273","article-title":"Efficacy and safety of fitusiran prophylaxis, an siRNA therapeutic, in a multicenter phase 3 study (ATLAS-INH) in people with hemophilia A or B, with inhibitors (PwHI)","volume":"138","author":"Young","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101164_bb0050","series-title":"WFH Online Registry of Clotting Factor Concentrates","year":"2018"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0038-1653753","article-title":"Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate","volume":"73","author":"Gu\u00e9rois","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/rth2.12094","article-title":"Product type and other environmental risk factors for inhibitor development in severe hemophilia A","volume":"2","author":"Peyvandi","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"10.1016\/j.blre.2023.101164_bb0065","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2023.101164_bb0070","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"Hacker","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2023.101164_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JBM.S43734","article-title":"Barriers and perceived limitations to early treatment of hemophilia","volume":"4","author":"Saxena","year":"2013","journal-title":"J Blood Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000121828","article-title":"Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective","volume":"119","author":"Khair","year":"2008","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0365","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.2830470312","article-title":"Inhibitors in hemophilia patients: current status and management","volume":"47","author":"Aledort","year":"1994","journal-title":"Am J Hematol"},{"issue":"s5","key":"10.1016\/j.blre.2023.101164_bb0370","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2516.2006.01379.x","article-title":"The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor","volume":"12","author":"N\u00c9GRIER","year":"2006","journal-title":"Haemophilia"},{"issue":"21","key":"10.1016\/j.blre.2023.101164_bb0090","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101164_bb0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JBM.S103796","article-title":"Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?","volume":"8","author":"Lieuw","year":"2017","journal-title":"J Blood Med"},{"issue":"s4","key":"10.1016\/j.blre.2023.101164_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2516.2006.01333.x","article-title":"Pharmacokinetics of recombinant factor VIII (Kogenate-FS\u00ae) in children and causes of inter-patient pharmacokinetic variability","volume":"12","author":"Barnes","year":"2006","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/hae.13466","article-title":"Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: two open-label studies","volume":"24","author":"Rusen","year":"2018","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.blre.2023.101164_bb0120","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.clinthera.2017.05.344","article-title":"An open-label, single-dose, pharmacokinetic study of factor VIII activity after administration of Moroctocog Alfa (AF-CC) in Male Chinese patients with hemophilia A","volume":"39","author":"Liu","year":"2017","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/14712590902729392","article-title":"Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A","volume":"9","author":"Shapiro","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2023.101164_bb0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/TCRM.S243146","article-title":"Safety and efficacy of Turoctocog alfa in the prevention and treatment of bleeding episodes in previously treated patients from China with severe hemophilia A: results from the Guardian 7 trial","volume":"16","author":"Wu","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/hae.12797","article-title":"Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(\u00ae)) in children with severe haemophilia A: efficacy, safety and pharmacokinetics","volume":"22","author":"Klukowska","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2023.101164_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719858471","article-title":"Efficacy and safety of simoctocog alfa (Nuwiq\u00ae) in patients with severe hemophilia A: a review of clinical trial data from the GENA program","volume":"10","author":"Lissitchkov","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101164_bb0145","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/hae.12952","article-title":"Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial","volume":"22","author":"Saxena","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2023.101164_bb0150","author":"U.S. Food and Drug Administration"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0155","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/jth.13647","article-title":"Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial","volume":"15","author":"Stasyshyn","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101164_bb0160","series-title":"ADYNOVATE Package Insert","author":"U.S. Food and Drug Administration","year":"2021"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0165","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101164_bb0170","author":"FDA"},{"issue":"11","key":"10.1016\/j.blre.2023.101164_bb0175","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0095","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood-2008-09-174649","article-title":"Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice","volume":"114","author":"Qadura","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101164_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2017.07.001","article-title":"To serve and protect: the modulatory role of von Willebrand factor on factor VIII immunogenicity","volume":"31","author":"Hartholt","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101164_bb0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/JBM.S82457","article-title":"Potential role of a new PEGylated recombinant factor VIII for hemophilia A","volume":"7","author":"Wynn","year":"2016","journal-title":"J Blood Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0185","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2133\/dmpk.24.318","article-title":"The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics","volume":"24","author":"Andersen","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.blre.2023.101164_bb0190","series-title":"Therapeutic Proteins","first-page":"157","article-title":"Half-life extension by fusion to the Fc region","author":"Jazayeri","year":"2012"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jps.23783","article-title":"Pharmacokinetics of peptide-fc fusion proteins","volume":"103","author":"Wu","year":"2014","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09205063.2020.1825304","article-title":"PEGYLATION: an important approach for novel drug delivery system","volume":"32","author":"Yadav","year":"2021","journal-title":"J Biomater Sci Polym Ed"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12079-018-0492-0","article-title":"Protein PEGylation for cancer therapy: bench to bedside","volume":"13","author":"Gupta","year":"2019","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0210","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/bc000061m","article-title":"New PEGs for peptide and protein modification, suitable for identification of the PEGylation site","volume":"12","author":"Veronese","year":"2001","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425240802650568","article-title":"PEG-modified biopharmaceuticals","volume":"6","author":"Bailon","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"10.1016\/j.blre.2023.101164_bb0220","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.blre.2023.101164_bb0225","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2023.101164_bb0230","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0235","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2516.2006.01388.x","article-title":"Defining \u2018full-length\u2019 recombinant factor VIII: a comparative structural analysis","volume":"13","author":"Jankowski","year":"2007","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.blre.2023.101164_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108584","article-title":"Plasma clearance of coagulation factor VIII and extension of its half-life for the therapy of hemophilia A: a critical review of the current state of research and practice","volume":"24","author":"Sarafanov","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0245","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/bi5011688","article-title":"Cluster III of low-density lipoprotein receptor-related protein 1 binds activated blood coagulation factor VIII","volume":"54","author":"Kurasawa","year":"2015","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.blre.2023.101164_bb0250","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.12985","article-title":"Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(\u00ae)) in patients with severe haemophilia A","volume":"22","author":"Klamroth","year":"2016","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2003-37935","article-title":"Structure and function of the factor VIII gene and protein","volume":"29","author":"Thompson","year":"2003","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0260","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/hae.13875","article-title":"PEGylated biologics in haemophilia treatment: current understanding of their long-term safety","volume":"26","author":"Baumann","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.blre.2023.101164_bb0265","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/hae.14123","article-title":"Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy","volume":"26","author":"Meeks","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2023.101164_bb0270","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","article-title":"Extension of in vivo half-life of biologically active molecules by XTEN protein polymers","volume":"240","author":"Podust","year":"2016","journal-title":"J Control Release"},{"issue":"26","key":"10.1016\/j.blre.2023.101164_bb0275","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"K\u00f6nigs","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0280","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/hae.14052","article-title":"Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia a","volume":"26","author":"Chowdary","year":"2020","journal-title":"Haemophilia"},{"issue":"9","key":"10.1016\/j.blre.2023.101164_bb0285","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0290","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1111\/hae.14319","article-title":"Safety and efficacy of BAY 94\u20139027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A","volume":"27","author":"Santagostino","year":"2021","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.blre.2023.101164_bb0295","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2016-01-687434","article-title":"Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia A","volume":"128","author":"Mahlangu","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0300","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia a","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0305","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/bloodadvances.2022007529","article-title":"The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A","volume":"7","author":"Male","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101164_bb0310","author":"Sanofi"},{"issue":"16","key":"10.1016\/j.blre.2023.101164_bb0315","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101164_bb0320","series-title":"11 - polypeptides: PASylation and XTEN, in engineering of biomaterials for drug delivery systems","first-page":"299","author":"Anand","year":"2018"},{"key":"10.1016\/j.blre.2023.101164_bb0325","author":"FDA"},{"issue":"13","key":"10.1016\/j.blre.2023.101164_bb0330","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101164_bb0335","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0340","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2023.101164_bb0345","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.08.023","article-title":"Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: results of the PROTECT VIII clinical trial","volume":"183","author":"Santagostino","year":"2019","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0350","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/hae.14294","article-title":"PROTECT VIII kids extension study: long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A","volume":"27","author":"Mancuso","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0355","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2023.101164_bb0360","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101164_bb0375","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2021-146147","article-title":"Evaluation of the safety of Emicizumab prophylaxis in persons with hemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies","volume":"138","author":"Howard","year":"2021","journal-title":"Blood"},{"issue":"10386","key":"10.1016\/j.blre.2023.101164_bb0380","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0140-6736(23)00514-7","article-title":"Fitusiran in haemophilia: a breakthrough drug with many unknowns","volume":"401","author":"Peyvandi","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2023.101164_bb0385","author":"Foundation, N.H"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0390","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.transci.2018.07.011","article-title":"Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors","volume":"57","author":"Teitel","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0395","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/hae.12621","article-title":"Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment","volume":"21","author":"Earnshaw","year":"2015","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101164_bb0400","first-page":"460","article-title":"Serpinpc in persons with severe hemophilia (PwH): updated results from a multi-center, multi-part","volume":"140","author":"Baglin","year":"2022","journal-title":"First-in-Human Study Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.blre.2023.101164_bb0410","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2516.2007.01516.x","article-title":"A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation","volume":"13","author":"Bysted","year":"2007","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.blre.2023.101164_bb0415","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/hae.13301","article-title":"PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding","volume":"23","author":"Wang","year":"2017","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0420","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/hae.14563","article-title":"Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors","volume":"28","author":"Pipe","year":"2022","journal-title":"Haemophilia"},{"issue":"14","key":"10.1016\/j.blre.2023.101164_bb0425","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0430","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101164_bb0435","article-title":"Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management","volume":"8","author":"Mahlangu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"23","key":"10.1016\/j.blre.2023.101164_bb0440","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PloS One"},{"issue":"21","key":"10.1016\/j.blre.2023.101164_bb0450","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2023.101164_bb0455","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.blre.2023.101164_bb0460","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/S2352-3026(19)30070-5","article-title":"The effect of emicizumab regimen on haemophilia outcomes","volume":"6","author":"Ragni","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101164_bb0465","series-title":"WFH guidelines for the Management of Hemophilia","first-page":"1","volume":"26 Suppl 6","author":"Srivastava","year":"2020"},{"issue":"24","key":"10.1016\/j.blre.2023.101164_bb0470","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2023.101164_bb0475","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jimenez-Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1016\/j.blre.2023.101164_bb0480","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia a without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.blre.2023.101164_bb0485","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia a (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101164_bb0490","author":"Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors"},{"issue":"9","key":"10.1016\/j.blre.2023.101164_bb0495","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.blre.2023.101164_bb0500","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMc1909742","article-title":"Deaths associated with Emicizumab in patients with hemophilia A","volume":"381","author":"Aledort","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2023.101164_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078732","article-title":"The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models","volume":"8","author":"Onasoga-Jarvis","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0515","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11239-006-6556-7","article-title":"Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases","volume":"21","author":"Girolami","year":"2006","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0520","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14212","article-title":"Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US","volume":"27","author":"Lewandowska","year":"2021","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.blre.2023.101164_bb0525","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0530","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment a United Kingdom Haemophilia Centre Doctors\u2019 organisation guideline","volume":"26","author":"Jenkins","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2023.101164_bb0535","series-title":"World Congress of the World Federation of Haemophilia (WFH) May","article-title":"Use of rotational thromboelastometry to monitor boys with severe haemophlia A and inhibitors on treatment with emicizumab","author":"Badle","year":"2018"},{"key":"10.1016\/j.blre.2023.101164_bb0540","series-title":"Haemophilia","article-title":"Effect of emicizumab (ACE910)-a humanized bispecific antibody mimicking FVIIIa cofactor function-on coagulation assays commonly in use for monitoring of hemophilia A patients","author":"Adamkewicz","year":"2017"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0545","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.blre.2023.101164_bb0550","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.blre.2023.101164_bib671","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A","volume":"119","author":"M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101164_bb0555","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2019-123820","article-title":"Determining the approximate factor VIII level equivalency of patients with severe hemophilia A on emicizumab using global hemostasis assays","volume":"134","author":"Kizilocak","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0560","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jama.290.1.113","article-title":"Industry funding of clinical trials: benefit or bias?","volume":"290","author":"Chopra","year":"2003","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.blre.2023.101164_bb0565","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"35","author":"Reyes","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0570","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.blre.2023.101164_bb0575","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JBM.S288283","article-title":"Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with hemophilia A without inhibitors: matching-adjusted indirect comparison of a-long and haven trials","volume":"12","author":"Klamroth","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2023.101164_bb0580","author":"EMA"},{"key":"10.1016\/j.blre.2023.101164_bb0585","author":"FDA"},{"issue":"11","key":"10.1016\/j.blre.2023.101164_bb0590","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2023.101164_bb0595","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101164_bb0600","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for haemophilia a using a novel human factor VIII variant","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0605","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2023.101164_bb0610","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2019-122143","article-title":"Updated follow-up of the Alta study, a phase 1\/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult patients with severe hemophilia A","volume":"134","author":"Konkle","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101164_bb0615","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2019-125764","article-title":"First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A","volume":"134","author":"Pipe","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2023.101164_bb0620","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2023.101164_bb0625","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2023.101164_bb0630","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2021-148651","article-title":"Updated results of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia A","volume":"138","author":"Visweshwar","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2023.101164_bb0635","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/hae.13747","article-title":"Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia a: combined analysis of three studies","volume":"25","author":"Volkers","year":"2019","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0640","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s41669-021-00283-6","article-title":"Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States","volume":"5","author":"Bullement","year":"2021","journal-title":"PharmacoEconomics - Open"},{"issue":"4","key":"10.1016\/j.blre.2023.101164_bb0645","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14347","article-title":"Real-world cost estimates of initiating emicizumab in US patients with haemophilia a","volume":"27","author":"Samelson-Jones","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0650","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0039-3401822","article-title":"Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia a patients with inhibitors","volume":"120","author":"Cortesi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"9_suppl","key":"10.1016\/j.blre.2023.101164_bb0655","doi-asserted-by":"crossref","first-page":"29s","DOI":"10.1177\/1076029618807583","article-title":"A practical guide to the management of the fetus and newborn with hemophilia","volume":"24","author":"Moorehead","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.blre.2023.101164_bb0660","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tracli.2021.01.008","article-title":"Hemophilia care in Africa: status and challenges","volume":"28","author":"Mbanya","year":"2021","journal-title":"Transfus Clin Biol"},{"issue":"9","key":"10.1016\/j.blre.2023.101164_bb0665","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2352-3026(22)00209-5","article-title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","volume":"9","author":"Pierce","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101164_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100033","article-title":"Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast","volume":"7","author":"Lambert","year":"2023","journal-title":"Res Practice Thromb Haemost"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:30Z","timestamp":1759437090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":134,"alternative-id":["S0268960X23001340"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101164","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101164"}}